Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: Implications for the treatment of alcoholism

Alcoholism: Clinical and Experimental Research

Volumn 22, Issue 7, 1998, Pages 1430-1436

  Schluger, James H ^a   Ho, Ann ^a   Borg, Lisa ^a   Porter, Margaret ^a   Maniar, Swapnil ^a   Gunduz, Mithat ^a   Perret, Guillaume ^a   King, Andrea ^a   Kreek, Mary Jeanne ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

ACTH; Cortisol; Nalmefene; Naloxone; Opioid Antagonist

Indexed keywords

ALCOHOL; CORTICOTROPIN; DELTA OPIATE RECEPTOR; HYDROCORTISONE; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; NALMEFENE; NALOXONE; NALTREXONE; OPIATE ANTAGONIST; PLACEBO;

AGED; ALCOHOLISM; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CORTICOTROPIN RELEASE; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; VOLUNTEER;

ADRENOCORTICOTROPIC HORMONE; ADULT; AGED; ALCOHOLISM; FEMALE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; PITUITARY-ADRENAL SYSTEM; TREATMENT OUTCOME;

EID: 0031756195     PISSN: 01456008     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1530-0277.1998.tb03931.x     Document Type: Article

References (69)

1. Pert CB, Snyder SH: Opiate receptors: Demonstration in nervous tissue. Science 179:1011-1014, 1973
2. 3H]etorphine to rat brain homogenate. Proc Natl Acad Sci USA 70:1947-1049, 1973
3. Terenius L: Stereospecific interaction between narcotic analgesics and a synaptic plasma membrane fraction of rat cerebral cortex. Acta Pharmacol Toxicol 32:317-320, 1973
4. Hughes J, Smith TW, Kosterlitz HW, Fothergil LA, Morgan BA, Morris HR: Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 258:577-579, 1975
5. Kreek MJ: Medical safety, side effects, and toxicity of methadone. Proceedings of the Fourth National Conference on Methadone Treatment, National Association for the Prevention of Addiction to Narcotics, New York, 1972, pp 171-174
6. Kreek MJ: Physiological implications of methadone treatment. Proceedings of the Fifth National Conference on Methadone Treatment, National Association for the Prevention of Addiction to Narcotics, New York, pg., 1973, pp 824-836
7. Kreek MJ: Medical complications in methadone patients. Ann NY Acad Sci 311:110-134, 1978
8. Cushman P, Kreek MJ: Some endocrinologic observations in narcotic addicts, in Zimmerman E, George R (eds): Narcotic and the Hypothalamus. New York, Raven Press, 1974, pp 161-173
9. Mains RE, Eipper BA, Ling N: Common precursor to corticotropins and endorphins. Proc Natl Acad Sci USA 74:3014-3018, 1977
10. Rubinstein M, Stein S, Udenfriend S: Characterization of proopiocortin, a precursor to opioid peptides and corticotropin. Proc Natl Acad Sci USA 75:669, 1978
11. Chretien M, Benjannet S, Gossard F, Gianolakis C, Crine P, Lis M, Siedah NG: From β-lipotropin to β-endorphin and 'pro-opiomelanocortin.' Can J Biochem 57:1111-1121, 1979
12. Kreek MJ: Medical management of methadone-maintained patients, in Lowinson JH, Ruiz P (eds): Substance Abuse Clinical Problems and Perspectives. Baltimore, Williams & Wilkins, 1981, pp 660-673
13. Kreek MJ, Wardlaw SL, Friedman J, Schneider B, Frantz AG: Effects of chronic exogenous opioid administration on levels of one endogenous opioid (beta-endorphin) in man, in Simon E, Tagaki H (eds): Advances in Endogenous and Exogenous Opioids. Tokyo, Kodansha Ltd. Publishers, 1981, pp 364-366
14. Kreek MJ: Health consequences associated with the use of methadone, in Cooper JR, Altman F, Brown BS, Czechowitz D (eds): Research in the Treatment of Narcotic Addiction: State of the Art. NIDA monograph, DHHS Publ. (ADM) 83-1281. Washington, D.C., NIDA, 1983, pp 456-482
15. Kreek MJ, Wardlaw SL, Hartman N, Raghunath J, Friedman J, Schneder B, Frantz AG: Circadian rhythms and levels of beta-endorphin, ACTH, and cortisol, during chronic methadone maintenance treatment in humans. Life Sci 33(Suppl. I):409-411, 1983
16. Kreek MJ, Schaefer RA, Hahn EF, Fishman J: Naloxone, a specific opioid antagonist, reverses chronic idiopathic constipation. Lancet Feb. 5:261-262, 1983
17. Kreek MJ, Raghunath J, Plevy S, Hamer D, Schneder B, Hartman N: ACTH, cortisol, and beta-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans. Neuropeptides 5:277-278, 1984
18. Cohen G, Collins M: Alkaloids from catecholamines in adrenal tissue: Possible role of alcoholism. Science 167:1749-1751, 1970
19. Davis EA, Walsh M: Alcohol, amines, and alkaloids: Possible biochemical basis of alcohol addiction. Science 167:1005-1006, 1970
20. Tabakoff B, Hellevuo K, Hoffman PL: Alcohol, in Schuster CR, Kuhar MJ (eds): Pharmacological Aspects of Drug Dependence. Handbook of Experimental Pharmacology, vol 118. Berlin, Springer, pp 9-17, 1996
21. Sandi C, Borrell J, Guaza C: Involvement of kappa opioids on ethanol drinking. Life Sci 42:1067-1075, 1988
22. Altshuler HL, Phillips PE, Feinhendler DA: Alteration of ethanol self-administration by naltrexone. Life Sci 26:879-888, 1980
23. Volpicelli JR, Alterman AI, Hayashida M, Obrien CP: Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49:876-880, 1992
24. O'Malley SS, Jaffe A, Chang G, Shottenfeld RS, Meyer RE, Rounsaville B: Naltexone and coping skills therapy for alcohol dependence: A controlled study. Arch Gen Psychiatry 49:881-887, 1992
25. Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, Mantero-Atienza E: A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res 18:1162-1167, 1994
26. Unterwald EM, Rubenfield JM, Imai Y, Wang J, Uhl GR, Kreek KJ: Chronic opioid antagonist administration upregulates mu opioid receptor binding without altering mu opioid receptor mRNA levels. Mol Brain Res 33:351-355, 1995
27. Zukin RS, Sugarman JR, Fitz-Syage ML, Gardner EL, Zukin SR, Gintzler AR: Naltrexone-induced opiate receptor supersensitivity. Brain Res 245:285-292, 1982
28. Unterwald EM, Home-King J, Kreek MJ: Chronic cocaine alters brain mu opioid receptors. Brain Res 584:314-318, 1992
29. Unterwald EM, Rubenfeld JM, Kreek MJ: Repeated cocaine administration upregulates kappa and mu, but not delta, opioid receptors. Neuroreport 5:1613-1616, 1994
30. Spangler R, Ho A, Zhou Y, Maggos C, Yferov V, Kreek MJ: Regulation of kappa opioid receptor mRNA in the rat brain by 'binge' pattern cocaine administration and correlation with preprodynorphin mRNA. Mol Brain Res 38:71-76, 1996
31. Spangler R, Zhou Y, Maggos CE, Schlussman SD, Ho A, Kreek MJ: Prodynorphin, proenkephalin, and kappa opioid receptor mRNA responses to acute "binge" cocaine. Mol Brain Res 44:139-142, 1997
32. Lorens SA, Sainati SM: Naloxone blocks the excitatory effects of ethanol and chlordiazepoxide on lateral hypothalamic self stimulation behavior. Life Sci 23:1359-1364, 1978
33. Esposito RU, Perry W, Kornetsky C: Effects of d-amphetamine and naloxone on brain stimulation reward. Psychopharmacology 69:187-191, 1980
34. Nazzaro JM, Gardner EL, Bridger WH, Carlson KR, Seeger TF: Pentobarbital induces a noloxone reversible decrease in mesocorticolimbic self-stimulation thresholds. Soc Neurosci Abstr 7:262, 1981
35. Bain GT, Kornetsky YC: Naloxone attenuation of the effect of cocaine on rewarding brain stimulation. Life Sci 40:1119-1125, 1987
36. 9-tetrahydrocannabinol is mediated through an endogenous opioid mechanism. Adv Biosci 75:671-674, 1989
37. Gardner EL, Lowinson JH: Marijuana's interaction with brain reward systems: Update 1991. Pharmacol Biochem Behav 40:571-580, 1991
38. Kosten TR, Kreek MJ, Raghunath J, Kleber HD: Cortisol levels during chronic naltrexone maintenance treatment in ex-opiate addicts. Biol Psychiatry 21:217-220, 1986
39. Kosten TR, Kreek MJ, Raghunath J, Kleber HD: A preliminary study of beta-endorphin during chronic naltrexone maintenance treatment in ex-opiate addicts. Life Sci 39:55-59, 1986
40. Kosten TR, Morgan C, Kreek MJ: Beta-endorphin levels during heroin, buprenorphine and naloxone challenges: Preliminary findings. Biol Psychiatry 32:523-528, 1992
41. Culpepper-Morgan JA, Inturrisi CE, Portenoy RK, Foley K, Houde RW, Marsh F, Kreek MJ: Treatment of opioid induced constipation with oral naloxone: A pilot study. Clin Pharmacol Ther 52:90-95, 1992
42. Culpepper-Morgan JA, Kreek MJ: HPA axis hypersensitivity to naloxone in opioid dependence: A case of naloxone induced withdrawal. Metab Clin Exp Res 46:130-134, 1997
43. Volavka J, Cho D, Mallya A, Bauman J: Naloxone increases ACTH and cortisol in man. N Engl J Med 300:1056-1057, 1979
44. Volavka J, Bauman J, Pevnick J, Reker D, James B, Cho D: Short-term hormonal effects of naloxone in man. Psychoneuroendocrinology 5:225-234, 1980
45. Morley J, Baranetsky NG, Wingert TW, Carleson HE, Hershman JM, Melmed S, Levin SR, Jamison KR, Weitzman R, Chang J, Varner AA: Endocrine effects of naloxone-induced opiate receptor blockade. J Clin Endocrinol Metab 50:251-257, 1980
46. Naber D, Pickar D, Davis GC, Cohen RM, Jimerson DC, Elchisak MA, Defraites EG, Kalin NH, Risch SC, Buchsbaum MS: Naloxone effects on β-endorphin, cortisol, prolactin, growth hormone, HVA, MHPG, in plasma of normal volunteers. Psychopharmacology 74:125-128, 1981
47. Cohen MR, Cohen RM, Pickar D, Weingartner H, Murphy DL: High-dose naloxone infusion in normals. Arch Gen Psychiatry 40:613-619, 1983
48. Kreek MJ, Schneder BS, Raghunath J, Plevy S: Prolonged (24 hour) infusion of the opioid antagonist naloxone does not significantly alter plasma levels of cortisol and ACTH in humans. Abstracts of the Seventh International Congress of Endocrinology. Amsterdam, Excerpta Medica, International Congress Series 652, 845, July 1984
49. Michel ME, Bolger G, Weissman BA: Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Methods Find Exp Clin Pharmacol 7:175-177, 1985
50. Dixon R, Gentile J, Hsu HB, Hsiao J, Howes J, Garg D, Weidler D: Nalmefene: Safety and kinetics after single and multiple oral doses of a new opioid antagonist. J Clin Pharmacol 27:233-239, 1987
51. Wilhelm JA, Vang-Pedersen P, Zakszewski TB, Osifchin E, Waters SJ: Duration of opioid antagonism in the dog. A nonparametric pharmacodynamic comparison based on generalized cross-validated spline estimation. Int J Clin Pharmacol Ther 33:540-545, 1995
52. Emerson PL, Liu M, Woods JH, Medzihradsky F: Binding affinity and selectivity of opioids at mu, delta, and kappa receptors in monkey brain membranes. J Pharmacol Exp Ther 271:1630-1637, 1994
53. Culpepper-Morgan JA, Holt PR, LaRoche D, Kreek MJ: Orally administered opioid antagonists reverse both mu and kappa opioid agonist delay of gastrointestinal transit in the guinea pig. Life Sci 56:1187-1192, 1995
54. Albeck H, Woodfield S, Kreek MJ: Quantitative and pharmacokinetic analysis of naloxone in plasma using high performance liquid chromatography with electrochemical detection and solid phase extraction. J Chromatogr 488:435-445, 1989
55. Chou JZ, Albeck H, Kreek MJ: Determination of nalmefene in plasma by high performance liquid chromatography with electrochemical detection and its application in pharmacokinetic studies. J Chromatogr 613:359-364, 1993
56. Biglino A, Limone P, Forno B, Pollono A, Cariti G, Molonatti GM, Gioannini P: Altered adrenocorticotropin and cortisol response to corticotropin-releasing hormone in HIV-1 infection. Eur J Endocrinol 133:173-179, 1995
57. Kreek MJ, Ochshorn M, Ferdinands L, O'Bryan L, Carty A: Hypothalamic-pituitary-adrenal (HPA) effects in humans of a new opioid antagonist nalmefene with mu and kappa receptor subtype activity. Abstracts of the 1987 INRC Conference, Adelaide, Australia, 1987
58. Grossman A, Besser GM: Opiates control ACTH through a noradrenergic mechanism. Clin Endocrinol 17:287-290, 1982
59. Delitela G, Palermo M, Tomasi P, Besser M, Grossman A: Adrenergic stimulation of the human pituitary-adrenal axis is attenuated by an analog of met-enkephalin. Neuroendocrinology 53:41-46, 1991
60. Delitela G, Trainer PJ, Oliva O, Fanciulli G, Grossman AB: Opioid peptide and α-adrenoreceptor pathways in the regulation of the pituitary adrenal axis in man. J Endocrinol 141:163-168, 1994
61. Plotsky PM: Opioid inhibition of immunoreactive corticotropin-releasing factor secretion into the hypophysial-portal circulation of rats. Regul Pept 16:235-242, 1986
62. Nikolarakis K, Pfeiffer A, Stalla GK, Herz A: The role of CRF in the release of ACTH by opiate agonists and antagonists in rats. Brain Res 421:373-376, 1987
63. Kim S, Wagner HN Jr, Villemagne VL, Kao PF, Dannals RF, Ravert HT, Joh T, Dixon RB, Civelek AC: Longer occupancy of opioid receptors by nalmefene compared to naloxone measured in vivo by a dual-detector system. J Nucl Med 38:1726-1731, 1997
64. Glass PS, Shaveri RM, Smith LR: Comparison of potency and duration of nalmefene and naloxone. Anesth Analg 78:536-541, 1994
65. Barsan WG, Seger D, Danzl DF, Ling LJ, Bartlett R, Buncher R, Bryan C: Duration of antagonist effects of nalmefene and naloxone in opiate-induced sedatin for emergency department procedures. Am J Emerg Med 7:155-161, 1989
66. France CP, Gerack LR: Behavioral effects of 6-methylene naltrex-one (nalmefene) on rhesus monkeys. J Pharmacol Exp Ther 270:992-999, 1994
67. Kreek MJ: Rationale for maintenance pharmacotherapy of opiate dependance, in O'Brien CP, Jaffe JH (eds): Addictive States. New York, Raven Press, Ltd., 1992, pp 205-230
68. Kreek MJ: Opiates, opioids, and addiction. Mol Psychol 1:232-254, 1996
69. Kreek MJ: Opioid receptors: Some perspectives from early studies of their role in normal physiology, stress responsivity, and in specific addictive diseases. J Neurochem Res 21:1469-1488, 1996